Prakash Agarwal, Equity Analyst - India Pharma, RBS is positive on Lupin and advises investor to buy on dips. In the largecap space, Cipla is his top pick He has a target price of Rs 371 on the stock. In the midcap space, he likes Glenmark Pharma.
However, he is bearish on Dr ReddyDiscover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!